
Oppenheimer raises Humana price target to $475 on strong Medicare Advantage ratings.
Oppenheimer upgraded Humana's price target from $405 to $475, citing strong performance in Medicare Advantage plans where 95% of members are in four-star or higher rated plans. This upgrade implies a potential 22.7% upside from Humana's current stock...





